Publications

Export 410 results:
Sort by: Author Title Type [ Year (Desc)]
2010
Ghnaim, W. A. - E., N. I. Ghali, and A. E. Hassanien, "Known-ciphertext cryptanalysis approach for the Data Encryption Standard technique", Computer Information Systems and Industrial Management Applications (CISIM), 2010 International Conference on: IEEE, pp. 600–603, 2010. Abstract
n/a
Hamza, H. S., J. Martinez, and J. L. Mugartza, "KOPLE: knowledge-oriented product line engineering", Proceedings of the ACM international conference companion on Object oriented programming systems languages and applications companion: ACM, pp. 275–276, 2010. Abstract
n/a
Hamza, H. S., J. Martinez, and J. L. Mugartza, "KOPLE: knowledge-oriented product line engineering", Proceedings of the ACM international conference companion on Object oriented programming systems languages and applications companion: ACM, pp. 275-276, 2010. Abstract
n/a
Abo-Madyan, Y., O. Aldabbas, G. Welzel, J. Schaefer, M. Puetz, M. Polednik, F. Lohr, and F. Wenz, "KOSIMA-study: comparison of cosmetic results of hypogractioned intensity modulated radiation therapy (IMRT) with fractionated radiation therapy (IMRT) in a case of breast cancer", STRAHLENTHERAPIE UND ONKOLOGIE, vol. 186: URBAN & VOGEL NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY, pp. 45–45, 2010. Abstract
n/a
2009
Mahmoud, H. K., Y. El Nahas, M. Abdel Moaty, R. Abdel Fattah, M. El Emary, and W. El Metnawy, "Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.", International journal of biomedical science : IJBS, vol. 5, issue 3, pp. 223-8, 2009 Sep. Abstract

PURPOSE: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML.

METHODS: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR.

RESULTS: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001).

DISCUSSION: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.

Mahmoud, H., Y. El Nahas, M. Abdel Moaty, R. Abdel Fattah, M. El Emary, and W. El Metnawy, "Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival.", International journal of biomedical science : IJBS, vol. 5, issue 3, pp. 223-8, 2009 Sep. Abstract
application/pdf iconkinetics_of_bcr-abl_transcripts_2009.pdf

PURPOSE: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML.

METHODS: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR.

RESULTS: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001).

DISCUSSION: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.

Fayek, M. B., E. N. A. Heba, and M. M. Moussa, "Keyframe selection from shots using Particle swarm optimization", Ain Shams Journal of Electrical Engineering (ASJEE), vol. 1, issue 1, 2009.
Mahmoud, H. K., Y. H. Elnahass, M. Abdel Moaty, R. Abdel Fattah, M. El Emary, and W. El Metnawy, "Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), a Predictor of Response and Progression free Survival", International journal of biomedical science, vol. 5, issue 3, pp. 223-228. , 2009. Abstract

Purpose: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML. Methods: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR. Results: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001). Discussion: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.

Ahmed, A., S. Ghoneim, and R. Kim, "Knowledge management as an enabler of change and innovation in Africa", Int. J. of Technology Management, vol. 45, issue No 1/2, pp. 10-26, 2009.
Selim, K. A., F. H. A. El-Rahiem, and A. A. El-Midany, "Kinetic Modelling and Equilibrium of Amphoteric Collector Adsorption on Silica and Hematite", Tenside Surfactants Detergents Journal For Theory Technology And Application, vol. 46, no. 2, pp. 85, 2009. Abstract
n/a
Sayyah, S. M., M. Rehahn, A. H. M. Elwahy, and M. T. H. Abou-Kana, "Kinetic studies on the dilatometric-free radical copolymerization of new modified laser dye monomer with methyl methacrylate and characterization of the obtained copolymer", Journal of applied polymer science, vol. 112, no. 4: Wiley Online Library, pp. 2462–2471, 2009. Abstract
n/a
Sayyah, S. M., M. Rehahn, A. H. M. Elwahy, and M. T. H. Abou-Kana, "Kinetic studies on the dilatometric-free radical copolymerization of new modified laser dye monomer with methyl methacrylate and characterization of the obtained copolymer", Journal of applied polymer science, vol. 112, no. 4: Wiley Online Library, pp. 2462–2471, 2009. Abstract
n/a
Mahmoud, H. K., Y. H. El Nahas, M. A. Samra, R. M. Abdelfattah, M. A. ElEmary, and W. H. El-Metnawy, "Kinetics Of BCR-ABL Transcripts In Patients with Chronic Phase CML (CML-CP) Treated With Imatinib Mesylate (Im): A Predictor Of Response And Progression Free Survival (PFS)", Haematologica, vol. 94, issue S2, pp. 573: Abst 1473., 2009.
application/pdf icon2009_kinetics_of_bcr-abl_transcripts_in_patients_with_cml-cp.pdf
2008
Galal-Edeen, G. H., and B. Tawfik, "Knowledge Creation in a Community: the Case for International Collaboration", Conference on Enhancing the Competitiveness of Universities, Faculty of Commerce, Cairo University, Cairo, Egypt, 4 th June 2008. Abstract

n/a

Ahmed, T. S., J. M. DeSimone, and G. W. Roberts, "Kinetics of the Homopolymerization of Vinylidene Fluoride and Its Copolymerization with Hexafluoropropylene in Supercritical Carbon Dioxide: The Locus of Polymerization", Macromolecules, vol. 42, issue 1: ACS Publications, pp. 148 - 155, 2008. Abstract

n/a

Salama, D. A. F. H., "Kaiser Friedrich II. von Hohenstaufen; ein Sultan über Europa? Die Rezeption der Figur des Stauferkaisers in literarischen Werken.", Kairoer Germanistische Studien, vol. 18, pp. 325-364, 2008. friedrich_ii._von_hohenstaufen.pdf
Soliman, A. M., "Kerwin Huelsman Newcomb Filter Using Inverting CCII", Active and Passive Electronic Devices, vol. 3, pp. 273–279, 2008. vol3_no_3-4khn_online_oct_2008.pdf
Darwish, H. A., N. A. H. Sadik, and O. M. Khowessah, "Ketoprofen microspheres for targeted drug delivery: Biochemical evaluation of their efficacy against colonic inflammation in rat", The Egyptian Journal of Biochemistry and Molecular Biology (EJBMB), vol. 26, pp. 392 – 407, 2008.
Hebatallah A. Darwish, Nermin A. H. Sadik, O. K., "Ketoprofen microspheres for targeted drug delivery: Biochemical evaluation of their efficacy against colonic inflammation in rats", The Egyptian Journal of Biochemistry and Molecular Biology (EJBMB), vol. 26, pp. 392 – 407, 2008.
Gharib Nevine M, Ismail Manal M., and A. S. M, "Kinematic and electromyographic analysis of knee motion during rising from a chair in stroke patients", Bulletin of Faculty of Physical Therapy, Cairo University, vol. 13, issue 2, pp. 73-85, 2008.
Hefnawy, E. T., "The Kissing Balloon and Stenting Technique for the Repair of Aorto-Iliac Bifuration Disease", Kasr Al-Ainy Journal of surgery , vol. Sept 9, pp. 3, 2008.
Galal-Edeen, G. H., and B. Tawfik, "Knowledge Creation in a Community: the Case for International Collaboration", Conference on Enhancing the Competitiveness of Universities, Faculty of Commerce, Cairo University, Cairo University, Egypt, Faculty of Commerce, Cairo University, 2008. Abstract

n/a

2007
S. Hanafi, K. Mostafa, A. H. W., "Kernel-Based Double Conjugated Clustering", Egyptian informatics Journal, vol. 8, issue 1, pp. 87-99, 2007. Abstract

n/a

Shoukry, A. A., Malgorzata Brindell, D. Piotrowska, and R. van Eldik, "Kinetics and mechanism of the reduction of (ImH) [trans- RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution", Journal of biological Inorganic chemistry, vol. 12, pp. 809-818, 2007.
Azza Shoukry, Malgorzata Brindell, and R. van Eldik, "Kinetics and mechanism of the substitution behaviour of Pd(II) piperazine complexes with different biologically relevant nucleophiles", Journal of Chemical Society, Dalton Trans.,, vol. 37, pp. 4169-4174, 2007.
Tourism